Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) EBIT (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed EBIT for 4 consecutive years, with -$2.3 million as the latest value for Q3 2025.

  • On a quarterly basis, EBIT fell 9.76% to -$2.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $138025.0, a 101.45% increase, with the full-year FY2024 number at -$1.7 million, up 67.59% from a year prior.
  • EBIT was -$2.3 million for Q3 2025 at 60 Degrees Pharmaceuticals, down from -$1.6 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $6.0 million in Q4 2024 to a low of -$4.2 million in Q2 2024.
  • A 4-year average of -$1.1 million and a median of -$1.6 million in 2023 define the central range for EBIT.
  • Peak YoY movement for EBIT: crashed 607.41% in 2023, then surged 415.67% in 2024.
  • 60 Degrees Pharmaceuticals' EBIT stood at -$684698.0 in 2022, then tumbled by 176.64% to -$1.9 million in 2023, then soared by 415.67% to $6.0 million in 2024, then plummeted by 138.89% to -$2.3 million in 2025.
  • Per Business Quant, the three most recent readings for SXTP's EBIT are -$2.3 million (Q3 2025), -$1.6 million (Q2 2025), and -$1.9 million (Q1 2025).